🟢 Crispr Therapeutics is trading 4.1% up today on weak July jobs data and rate-cut hopes

Crispr Therapeutics is trading 4.1% up at $53.78, supported primarily by a broader biotech rally and renewed risk appetite after unexpectedly weak July employment data increased expectations for Federal Reserve rate cuts.

• The biotech XBI ETF is up 2.09%, while the Nasdaq is up 0.85%.
• No new Crispr Therapeutics announcement was identified for August 7, 2026. The company’s August 3 update highlighted stronger CASGEVY revenue and upcoming pipeline milestones, but the source did not directly link it to today’s move.